|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
Valuation Estimation |
EPS (Current/Estimated)
-1.23/-1.24
|
Enterprise Value
271.76M
|
Balance Sheet |
Book Value Per Share
3.83
|
Cash Flow |
Cash Flow Yield
--
|
Income Statement |
Total Revenue
0
|
Operating Revenue Per Share
0.13
|
Industry Comparison
|
||||||||||||||||||||||||||||||||||||||||||||||||
|

Industry overview quotes are at least 15 minutes delayed
Business Description
|
|||
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotopeLead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. |